Revance Therapeutics Inc at Guggenheim Healthy Altitudes Summit Transcript
All right. Thanks, everybody. So we're joined by Toby Schilke. In a second, we're going to talk about Revance Therapeutics. A little bit of a break from the biotech high science thought process and moving into really what I think is probably one of the more exciting consumer opportunities and biotech product launches that we're going to see over the next, probably year or so.
So Toby, thanks for joining us. Love to just -- maybe you can kick us off and remind people, remind everybody here what Revance is all about on the aesthetic side and then also there's the therapeutic opportunity.
Thanks, Seamus. So yeah, we were approved last September for DAXXIFY, which is launching into a relatively mature market in facial aesthetics. Companies have been around there for two decades, dominated by Allergan with three other approved products in the treatment of glabellar lines. This is a cash-pay market and really dominated by Allergan.
However, DAXXIFY has
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |